E. coli (52) |
|
|
ESBL (37) |
|
|
blaCTX-M-2 (8) |
SP (77 CLSI. M100Ed29E. Performance Standards for Antimicrobial Susceptibility Testing: 29th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.), RJ (1) |
|
blaCTX-M-8 (11) |
SP (99 EUCAST. Breakpoint tables for interpretation of MIC’s and zone diameters, version 8.0, January 2019. Växjö, Sweden:European Committee on Antimicrobial Susceptibility Testing;2019, http//www.eucast.org/fileadmin/src/media/PDFs/EUCAST files/Breakpoint tables/v 9.0 Breakpoint Tables.pdf. http//www.eucast.org/fileadmin/src/media...
), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
blaCTX-M-9 (2) |
RJ (2) |
|
blaCTX-M-14 (3) |
SP (3) |
|
blaCTX-M-15 (13) |
SP (1111 Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN. Antimicrobial Resistance Surveillance and New Drug Development. Open Forum Infect Dis. 2019;6(Suppl 1):S5-S13. https://doi.org/10.1093/ofid/ofy345...
), RJ (2) |
|
Carbapenemase (4) |
|
|
blaKPC-2(4) |
SP (22 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (22 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
|
|
|
E. cloacae (12) |
|
|
ESBL (12) |
|
|
blaCTX-M-15 (11) |
SP (1111 Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN. Antimicrobial Resistance Surveillance and New Drug Development. Open Forum Infect Dis. 2019;6(Suppl 1):S5-S13. https://doi.org/10.1093/ofid/ofy345...
), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
BlaSHV-12(1) |
SP (1) |
|
Carbapenemase (1) |
|
|
blaKPC-2(1) |
Salvador (1) |
|
P. mirabilis (3) |
|
|
ESBL (3) |
|
|
blaCTX-M-2 (1) |
RJ (1) |
|
blaCTX-M-8 (1) |
SP (1) |
|
blaCTX-M-15 (1) |
SP (1) |
|
|
|
|
K. pneumoniae (238)
|
|
|
ESBL (173) |
|
|
blaCTX-M-2 (43) |
SP (43) |
blaKPC-2 (32) |
blaCTX-M-3 (1) |
SP (1) |
|
blaCTX-M-8 (6) |
SP (44 Boletim Segurança do Paciente e Qualidade em Serviços de Saúde nº 17: Avaliação dos indicadores nacionais das infecções relacionadas à assistência à saúde (IRAS) e resistência microbiana do ano de 2017. Published on April 29th, 2019 https://app.powerbi.com/view?r=eyJrIjoiZTFiOGRhOTYtYzZjOS00NmZmLWE5MWUtN2RkNDhiZGJiOGE1IiwidCI6ImI2N2FmMjNmLWMzZjMtNGQzNS04MGM3LWI3MDg1ZjVlZGQ4MSJ. Last accessed on September 23rd, 2019. https://app.powerbi.com/view?r=eyJrIjoiZ...
), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
blaKPC-2 (2) |
blaCTX-M-9 (3) |
SP (3) |
|
blaCTX-M-14 (34) |
SP (34) |
blaKPC-2 (33) |
blaCTX-M-15 (84) |
SP (56), RJ (1717 Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother. 2017;72(1):268-272. https://doi.org/10.1093/jac/dkw374...
), Salvador (11) |
blaKPC-2 (38); blaNDM-1(2) |
blaCTX-M-35 (2) |
SP (2) |
|
blaCTX-M-141 (1) |
Salvador (1) |
blaKPC-2 (1) |
|
|
|
AmpC (2) |
|
|
blaCMY-2 (1) |
SP (1) |
|
blaCMY-141(1) |
SP (1) |
|
|
|
|
Carbapenemase (165) |
|
|
blaKPC-2 (163) |
SP (148), RJ (77 CLSI. M100Ed29E. Performance Standards for Antimicrobial Susceptibility Testing: 29th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.), Salvador (8) |
|
blaKPC-3 (1) |
SP (1) |
|
blaKPC-30 (1) |
SP (1) |
|
blaNDM-1 (2) |
RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
|
|
|
P. aeruginosa (104)
|
|
|
PDC (104) |
|
|
PDC-1 (4) |
SP (22 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
PDC-3 (11) |
SP (88 Brazilian Committee on Antimicrobial Susceptibility Testing – BrCAST. http://brcast.org.br/documentos/. http://brcast.org.br/documentos/...
), RJ (3) |
|
PDC-5 (15) |
SP (1313 Yin D, Wu S, Yang Y, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4), e02431-18. Published 2019 Mar 27. doi:10.1128/AAC.02431-18. https://doi.org/10.1128/AAC.02431-18....
), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
blaIMP-1 in SP (1); blaSPM-1 in SP (2) |
PDC-6 (1) |
SP (1) |
|
PDC-8 (8) |
SP (8) |
|
PDC-10 (1) |
SP (1) |
|
PDC-11 (3) |
SP (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
PDC-12 (3) |
SP (3) |
|
PDC-16 (11) |
SP (99 EUCAST. Breakpoint tables for interpretation of MIC’s and zone diameters, version 8.0, January 2019. Växjö, Sweden:European Committee on Antimicrobial Susceptibility Testing;2019, http//www.eucast.org/fileadmin/src/media/PDFs/EUCAST files/Breakpoint tables/v 9.0 Breakpoint Tables.pdf. http//www.eucast.org/fileadmin/src/media...
), Salvador (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.), RJ (11 CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.) |
|
PDC-19A (8) |
SP (66 Van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460-469.), Salvador (2) |
blaVIM-2 in SP (1) |
PDC-24 (2) |
SP (2) |
|
PDC-31 (1) |
RJ (1) |
|
PDC-35 (19) |
SP (19) |
blaIMP-74 in SP (1); blaCTX-M-2 in SP (3); blaGES-1 in SP (2); |
PDC-36 (1) |
SP (1) |
|
PDC-37 (4) |
SP (3), Salvador (1) |
blaKPC-2 in SP (1) |
PDC-45 (1) |
SP (1) |
|
PDC-55 (1) |
Salvador (1) |
|
PDC-59 (1) |
SP (1) |
blaCTX-M-2 in SP (1) |
PDC-109 (1) |
SP (1) |
|
PDC-115 (2) |
SP (2) |
|
PDC-120 (1) |
SP (1) |
|
PDC-124 (1) |
SP (1) |
|
PDC-194 (1) |
SP (1) |
|
PDC-218 (1) |
SP (1) |
|
PDC-252 (1) |
SP (1) |
|
PDC-253 (1) |
SP (1) |
|